Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hailiang Hu

Showing results (91-100 of 100) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 100 results.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 4, 2012
Aberrant overexpression of miR-421 downregulates ATM and leads to a pronounced DSB repair defect and clinical hypersensitivity in SKX squamous cell carcinomaWael Y Mansour, Natalia V Bogdanova, Ulla Kasten-Pisula, et al.
Cell Death & Disease|May 29, 2026
Ferroptosis vulnerability of enzalutamide resistant prostate cancer conferred by ACSL4 overexpression and GPX4 antagonismYi Zhou, Jiapeng He, Haozhe Zhang, et al.
Cell Death & Disease|January 7, 2023
A potassium-chloride co-transporter promotes tumor progression and castration resistance of prostate cancer through m<sup>6</sup>A reader YTHDC1Shuai Yuan, Shao-Hua He, Lu-Yao Li, et al.
Nature Chemical Biology|January 9, 2025
Chemically engineered antibodies for autophagy-based receptor degradationBinghua Cheng, Meiqing Li, Jiwei Zheng, et al.
Cell Death and Differentiation|October 31, 2023
YTHDC1 as a tumor progression suppressor through modulating FSP1-dependent ferroptosis suppression in lung cancerShuai Yuan, Shu Xi, Hong Weng, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 23, 2021
A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancerLingfan Xu, Yu Yin, Yanjing Li, et al.
Cancer Research|December 19, 2025
Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor CellsJianyang Hu, Binyu Zhang, Junhao Chen, et al.
Neoplasia (New York, N.Y.)|October 4, 2024
Prenatal p25-activated Cdk5 induces pituitary tumorigenesis through MCM2 phosphorylation-mediated cell proliferationYingwei Huang, Qiqi Wang, Weiwei Zhou, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 23, 2025
A PHF19-YTHDC1 condensate switches EZH2-mediated gene suppression to activation for prostate cancer progressionShuai Yuan, Dao-Jing Ming, Jiapeng He, et al.
Science Translational Medicine|December 6, 2019
Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancerYanjing Li, Yiping He, William Butler, et al.
Pageof 10

Showing results (91-100 of 100) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 4, 2012
Aberrant overexpression of miR-421 downregulates ATM and leads to a pronounced DSB repair defect and clinical hypersensitivity in SKX squamous cell carcinomaWael Y Mansour, Natalia V Bogdanova, Ulla Kasten-Pisula, et al.
Cell Death & Disease|May 29, 2026
Ferroptosis vulnerability of enzalutamide resistant prostate cancer conferred by ACSL4 overexpression and GPX4 antagonismYi Zhou, Jiapeng He, Haozhe Zhang, et al.
Cell Death & Disease|January 7, 2023
A potassium-chloride co-transporter promotes tumor progression and castration resistance of prostate cancer through m<sup>6</sup>A reader YTHDC1Shuai Yuan, Shao-Hua He, Lu-Yao Li, et al.
Nature Chemical Biology|January 9, 2025
Chemically engineered antibodies for autophagy-based receptor degradationBinghua Cheng, Meiqing Li, Jiwei Zheng, et al.
Cell Death and Differentiation|October 31, 2023
YTHDC1 as a tumor progression suppressor through modulating FSP1-dependent ferroptosis suppression in lung cancerShuai Yuan, Shu Xi, Hong Weng, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 23, 2021
A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancerLingfan Xu, Yu Yin, Yanjing Li, et al.
Cancer Research|December 19, 2025
Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor CellsJianyang Hu, Binyu Zhang, Junhao Chen, et al.
Neoplasia (New York, N.Y.)|October 4, 2024
Prenatal p25-activated Cdk5 induces pituitary tumorigenesis through MCM2 phosphorylation-mediated cell proliferationYingwei Huang, Qiqi Wang, Weiwei Zhou, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 23, 2025
A PHF19-YTHDC1 condensate switches EZH2-mediated gene suppression to activation for prostate cancer progressionShuai Yuan, Dao-Jing Ming, Jiapeng He, et al.
Science Translational Medicine|December 6, 2019
Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancerYanjing Li, Yiping He, William Butler, et al.
Pageof 10